NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare ...

A newly approved pain medication, suzetrigine, is the first nonopioid analgesic in 25 years to receive clearance from the U.S ...

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

Vertex Pharmaceuticals dominates the market ... Sionna has mapped out a clinical trial strategy that could validate its different approach to the chronic respiratory disease.

Pain, as Vertex Pharmaceuticals found out ... Supporting Vertex’s case are a pair of large clinical trials that assessed Journavx in people who underwent either a “tummy tuck” or a bunion ...

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...

To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...

Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) ...

Good day, and welcome to the Vertex Pharmaceuticals Fourth Quarter ... who participated in the clinical trials and made this approval possible. With these two recent approvals for ALYFTREK and ...

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc ... providers who participated in the clinical trials and made this approval possible.

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart Arbuckle ... the patients and healthcare providers who participated in the clinical trials and made ...